Solerte et al., in a multicentre, case-control, retrospective study on 338 patients with T2DM hospitalized for COVID-19, showed that sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment (insulin) and with an improvement in clinical outcomes, decreased risk for the need for mechanical ventilation, reduced risk for the need for I.C.U. admission, and with a greater number of hospital discharges compared with patients receiving standard of care, respectively (Table 1). Here, INS is linked to COVID-19.